CCL11 and myeloid sarcoma: Although changes in serum Eotaxin are not known to be directly associated with IFNβ treatment, it is regulated by Th2 cell mediated cytokines [30], which play a significant role in the IFNβ treatment mechanism [31] is also found to be reduced in CSF from people with MS as compared to HC [32].